| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/BF01972709 |
| P698 | PubMed publication ID | 8273575 |
| P2093 | author name string | K D Rainsford | |
| P2860 | cites work | Ultrastructural observations on the pathogenesis of aspirin-induced gastric erosions. | Q36091325 |
| Lipid mediators of inflammation in gastric ulcer | Q38140653 | ||
| Leukotrienes C4 and D4 potentiate acid production by isolated rat parietal cells | Q42493994 | ||
| Identification and isolation of a membrane protein necessary for leukotriene production | Q59059824 | ||
| The effects of 5-lipoxygenase inhibitors and leukotriene antagonists on the development of gastric lesions induced by nonsteroidal antiinflammatory drugs in mice | Q69460927 | ||
| Evidence for differing leukotriene receptors in gastric mucosa | Q70146020 | ||
| A profile of the gastric ulcerogenic activity of benoxaprofen compared with other nonsteroidal anti-inflammatory drugs in rats, stressed or given alcohol, and in pigs | Q70369716 | ||
| Relationship of gastric mucosal damage induced in pigs by antiinflammatory drugs to their effects on prostaglandin production | Q72040292 | ||
| P304 | page(s) | C24-6 | |
| P577 | publication date | 1993-01-01 | |
| P1433 | published in | Agents and Actions | Q23928727 |
| P1476 | title | Leukotrienes in the pathogenesis of NSAID-induced gastric and intestinal mucosal damage | |
| P478 | volume | 39 Spec No |
| Q35959365 | A randomized, double blind, placebo and active comparator controlled pilot study of UP446, a novel dual pathway inhibitor anti-inflammatory agent of botanical origin |
| Q42376883 | Aspirin treatment and increased generation of cysteinyl leukotrienes in Kawasaki disease |
| Q51587414 | Chronic effects of misoprostol in combination with the NSAID, diclofenac, on gastrointestinal tract of pigs. Relation to diarrheagenic activity, leukocyte infiltration, and mucosal leukotrienes. |
| Q40165582 | Discovery of dual inhibitors of the immune cell PI3Ks p110delta and p110gamma: a prototype for new anti-inflammatory drugs |
| Q51569802 | Effects of chronic treatment with indomethacin at clinically relevant doses on intestinal tissue 6-keto prostaglandin F1 alpha and leukotriene B4 level in relation to gastroenteropathy. |
| Q42548689 | Effects of tepoxalin, a dual inhibitor of cyclooxygenase/5-lipoxygenase, on events associated with NSAID-induced gastrointestinal inflammation |
| Q37170511 | Finding multiple target optimal intervention in disease-related molecular network. |
| Q35098944 | Flavocoxid inhibits phospholipase A2, peroxidase moieties of the cyclooxygenases (COX), and 5-lipoxygenase, modifies COX-2 gene expression, and acts as an antioxidant |
| Q34388999 | Flavocoxid, a dual inhibitor of cyclooxygenase‐2 and 5‐lipoxygenase, reduces pancreatic damage in an experimental model of acute pancreatitis |
| Q38253044 | Flavocoxid, a nutraceutical approach to blunt inflammatory conditions. |
| Q28190071 | Gastric mucosal integrity: gastric mucosal blood flow and microcirculation. An overview |
| Q92403172 | Ginkgolic Acid is a Multi-Target Inhibitor of Key Enzymes in Pro-Inflammatory Lipid Mediator Biosynthesis |
| Q62984494 | In vitro and ex vivo pharmacodynamics of selected non-steroidal anti-inflammatory drugs in equine whole blood |
| Q52322716 | Molecular modelling insights into a physiologically favourable approach to eicosanoid biosynthesis inhibition through novel thieno[2,3-b]pyridine derivatives. |
| Q26784322 | NSAIDs and Cardiovascular Diseases: Role of Reactive Oxygen Species |
| Q51387865 | Oral administration of tepoxalin in the horse: a PK/PD study. |
| Q34616021 | Sulindac sulfide suppresses 5-lipoxygenase at clinically relevant concentrations |
| Q35630102 | The shunt from the cyclooxygenase to lipoxygenase pathway in human osteoarthritic subchondral osteoblasts is linked with a variable expression of the 5-lipoxygenase-activating protein |
| Q35132201 | Therapeutic role of dual inhibitors of 5-LOX and COX, selective and non-selective non-steroidal anti-inflammatory drugs. |
| Q80562185 | [Management of the digestive risk in patients treated with NSAIDs. Synthesis and perspectives] |
| Q79343351 | [Therapy with nonsteroidal anti-inflammatory drugs] |
Search more.